The purpose of the webinar is to provide an overview of Aptahem's strategic direction, ongoing preparations for a planned U.S. listing, and recent key regulatory developments. The English-language event follows the Company's Swedish webinar held on September 22 and is intended to make Aptahem's current strategic initiatives accessible to a broader international audience. It will, in broad terms, cover the same topics presented during the Swedish-language webinar did.

Webinar details:

Register here: https://www.bigmarker.com/ir-live/join-aptahem-s-webinar-strategic-vision-and-planned-u-s-listing  

Date & Time: Wednesday, October 29, 2025, at 3:00-4:00 p.m. CEST

Language: English

Presenter: Mikael Lindstam, CEO, Aptahem AB

Agenda and key topics:

During the webinar, CEO Mikael Lindstam will provide an update on the Company's progress toward a planned U.S. listing and discuss the ongoing work to strengthen Aptahem's financial, regulatory, and structural readiness. Key topics will include:

• The strategic rationale and expected benefits of a U.S. listing.
• Progress in the transition to IFRS accounting and the preparation for U.S. auditor engagement.
• Recent regulatory initiatives, including the company's application to the FDA's PreCheck Program, which aims to support faster and higher-quality regulatory processes.
• Expansion of Aptahem's U.S. patent portfolio through a provisional application covering new indication areas for the lead candidate Apta-1.
• Next steps in advancing toward the planned Phase 2 clinical program.

Participants will have the opportunity to submit questions during the event. The webinar will be recorded and made available on the Company's website following the event.

CEO Mikael Lindstam comments

"As we continue to advance Aptahem's strategic transformation, it is important for us to communicate our direction clearly to all stakeholders, who already are or will be interested in our Company. This webinar provides an opportunity to present our progress and future ambitions to an international audience, as we work to create the foundation for Aptahem's next development phase and planned U.S. listing."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
Epost: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.